InterCure (INCR) Competitors

ORIC Pharmaceuticals (NASDAQ:ORIC) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Is ORIC or INCR more profitable?

ORIC Pharmaceuticals' return on equity of 0.00% beat InterCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ORIC Pharmaceuticals	N/A	-38.08%	-34.82%
InterCure	N/A	N/A	N/A

Which has better earnings & valuation, ORIC or INCR?

InterCure has higher revenue and earnings than ORIC Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ORIC Pharmaceuticals	N/A	N/A	-$100.70M	-$1.80	-5.01
InterCure	$96.61M	1.42	-$16.83M	$0.13	23.23

Which has more risk & volatility, ORIC or INCR?

ORIC Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in ORIC or INCR?

95.1% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 5.6% of ORIC Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of InterCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor ORIC or INCR?

ORIC Pharmaceuticals received 44 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 66.20% of users gave ORIC Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
ORIC Pharmaceuticals	Outperform Votes 47 66.20%	Underperform Votes 24 33.80%
InterCure	Outperform Votes 3 100.00%	Underperform Votes No Votes

Do analysts rate ORIC or INCR?

ORIC Pharmaceuticals currently has a consensus target price of $20.00, indicating a potential upside of 121.98%. Given InterCure's higher possible upside, equities analysts plainly believe ORIC Pharmaceuticals is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ORIC Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
InterCure	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Does the media prefer ORIC or INCR?

In the previous week, ORIC Pharmaceuticals had 3 more articles in the media than InterCure. MarketBeat recorded 7 mentions for ORIC Pharmaceuticals and 4 mentions for InterCure. InterCure's average media sentiment score of 0.83 beat ORIC Pharmaceuticals' score of 0.69 indicating that ORIC Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ORIC Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InterCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InterCure beats ORIC Pharmaceuticals on 8 of the 15 factors compared between the two stocks.